Fluciclovine (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
Status:
Recruiting
Trial end date:
2028-07-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well fluciclovine positron emission tomography (PET)/computed
tomography (CT) site-directed therapy works for treating patients with prostate cancer.
Fluciclovine PET/CT may detect prostate cancer early and may help to show whether patients
benefit from site directed treatment to PET detected abnormalities.
Phase:
Phase 2
Details
Lead Sponsor:
University of Washington
Collaborators:
Blue Earth Diagnostics National Cancer Institute (NCI)